Gout in primary care: getting to target — and what to do when you can't

1. Why this guide

Gout is the commonest inflammatory arthritis and one of the few we can effectively switch off — yet it remains badly managed almost everywhere. Patients are treated for their flares and discharged; urate-lowering therapy (ULT) is started but never titrated; nobody checks the serum urate; and a few years later the same patient returns with tophi and erosions. The guidelines have agreed on what good care looks like for over a decade. The gap is in execution.

This guide is written peer-to-peer for primary care. It summarises where the major guidelines agree (and where they diverge), translates that into what to actually do in clinic, and then spends most of its length on the part that is genuinely hard: the patient whose gout is not coming under control. It is free to use and adapt in your own practice.

2. The evidence at a glance

Seven contemporary guidelines inform this piece: ACR 2020 (US), EULAR 2016/2018 (Europe), BSR 2017 (UK), NICE NG219 2022 (UK), ACE Singapore 2023 (our local appropriate-care guide), APLAR 2021 (Asia-Pacific) and the 2024 Chinese update. A full side-by-side comparison sits at the end of this article.

On the fundamentals they are strikingly concordant: treat-to-target guided by serial serum urate; target <0.36 mmol/L (<0.30 for tophaceous/severe disease); allopurinol first-line, start-low-go-slow; low-dose colchicine for flares; and 3–6 months of flare prophylaxis when starting ULT. The G-CAN 2025 remission definition gives a clean endpoint: no flares, no subcutaneous tophi, and serum urate <0.36 mmol/L sustained over 12 months.

3. Diagnosis essentials

• Crystal identification remains the gold standard — needle-shaped, negatively birefringent MSU crystals on polarised microscopy. Do not diagnose gout on hyperuricaemia alone (EULAR 2018).
• A classic presentation (rapid-onset, intensely inflamed first MTP/midfoot/ankle, recurrent) supports a confident clinical diagnosis without aspiration.
• Always exclude septic arthritis — fever, systemic upset, atypical joint, immunosuppression or prosthesis should prompt aspiration. When in doubt, aspirate.
• Serum urate is often normal/low during a flare — recheck 2–4 weeks afterwards for a true baseline.
• Imaging (ultrasound double-contour sign; dual-energy CT) supports diagnosis when crystal ID is impractical and quantifies crystal burden over time (EULAR 2023).

4. Treat-to-target: the core discipline

This is the single most important habit in gout care, and the one most often missing. One number: serum urate <0.36 mmol/L (and <0.30 mmol/L while tophi are present, relaxing to <0.36 once they resolve). Below the saturation point, crystals dissolve, flares stop and tophi shrink. Treating the patient's symptoms — reacting only to flares — lets crystal load grow silently between attacks.

In practice: start ULT, recheck urate every 2–4 weeks and adjust until target is reached, then monitor every 3–6 months, then 6–12 monthly. Lifelong. The treat-to-target toolkit does the titration arithmetic and plots readings against the target line.

5. Urate-lowering therapy, done right

Who needs ULT, and when

Indications span a spectrum, from "offer to all at diagnosis" (BSR, EULAR) to threshold-based (ACR, ACE Singapore: ≥2 flares/year, any tophus, or radiographic damage). The pragmatic position is to start the conversation early — after a second flare, and after a first flare with CKD stage ≥3, urate >0.54 mmol/L, or urolithiasis. Starting ULT during a flare is now acceptable (ACR) with prophylaxis, and established ULT should never be stopped during a flare.

Allopurinol — first-line for nearly everyone

• Start ≤100 mg/day — and 50 mg/day (or alternate-day) if eGFR <30.
• Titrate by 100 mg (50 mg if eGFR <60) every 2–4 weeks until target is met.
• Do not stop at 300 mg, and do not cap by renal function. The dose can be pushed with monitoring to a maximum of 900 mg/day; in CKD titrate more slowly and watch closely, but the target is unchanged.
• Counsel every patient on SCAR warning signs, especially in the first 8 weeks (see §7).

The commonest reason allopurinol "doesn't work" is that it was left at 100–300 mg and never titrated.

When has allopurinol actually failed?

Before calling it failure, exclude the pseudo-failures the difficult-gout audit catches — non-adherence, under-titration, absent prophylaxis, or nobody checking the urate. True allopurinol failure is one of:

1. Inadequate response — urate persistently above target despite titration to the maximum tolerated dose;
2. Intolerance — SCAR/hypersensitivity or other limiting adverse effects;
3. Contraindication — HLA-B*5801 positivity.

Only then move along the ladder below.

Febuxostat — and choosing between the two xanthine oxidase inhibitors

Febuxostat is a potent non-purine selective XOI and the usual next step when allopurinol fails or is contraindicated. It carries no HLA-B*5801 SCAR association and retains efficacy in mild–moderate renal impairment. Dose: start 40 mg/day, increase to 80 mg/day (some guidelines allow 120 mg), titrating to target; continue flare prophylaxis, as the initial urate drop is brisk.

Efficacy — why allopurinol still leads. Head-to-head, febuxostat is more potent at fixed doses: in the FACT and CONFIRMS trials, febuxostat 80 mg got far more patients to target than allopurinol capped at 300 mg (67% vs 42% in CONFIRMS). But those trials never titrated allopurinol — dosed to target (often 400–600 mg), it largely closes the gap. That is why guidelines keep allopurinol first-line: equally effective when properly dosed, cheaper, and with the longest safety record.

Where febuxostat earns its place as the second-line XOI: when allopurinol has failed (not at target on the maximum tolerated dose) or is not tolerated; when the patient is HLA-B*5801 positive (no equivalent SCAR liability); or in CKD, where febuxostat needs no renal dose adjustment down to about eGFR 30 and retains efficacy, whereas allopurinol's renally-cleared oxypurinol demands caution.

The cardiovascular caveat — and how to weigh it. The CARES trial (2018), in gout patients with established cardiovascular disease, found higher cardiovascular and all-cause mortality with febuxostat versus allopurinol (despite non-inferior MACE), prompting a regulatory boxed warning — but it was undermined by ~50% treatment discontinuation and loss to follow-up. The larger, better-retained FAST trial (2020) found no excess mortality or CV events, and subsequent meta-analyses concur. The signal is therefore widely regarded as unconfirmed, yet residual uncertainty remains specifically in patients with established cardiovascular disease, where ACR and NICE still prefer allopurinol and the US FDA boxed warning keeps febuxostat second-line. Practically: in significant CVD, favour allopurinol; if febuxostat is needed, discuss the uncertainty, use the lowest effective dose, and optimise CV risk factors.

The Singapore lens. Because HLA-B*5801 is common locally (~1 in 5 Chinese), the allopurinol-SCAR risk weighs more heavily here than in Western cohorts — which is why the 2024 Chinese guideline is notably more febuxostat-forward, accepting it first-line, including in CKD. For most patients allopurinol remains first-line via the HLA-B*5801 shared-decision pathway (§7), but febuxostat's role is correspondingly larger in HLA-positive and CKD patients than the Western guidelines imply.

A note on "pleiotropic" effects. Because xanthine oxidase also generates reactive oxygen species, febuxostat has been proposed to have benefits beyond urate lowering — but the evidence is thin. A post-hoc analysis of the open-label PRIZE trial found small, transient reductions in non-HDL-cholesterol, triglycerides and an oxidative-stress marker (MDA-LDL) at 6 months, with no significant effect on LDL-cholesterol, and the differences had gone by 24 months; the one renal-outcome RCT (FEATHER) was negative for its primary endpoint. Treat these as hypothesis-generating, not a reason to choose febuxostat.

Uricosurics — and exactly when to consider them

Around 90% of gout is driven by renal under-excretion, which is what uricosurics target (URAT1 inhibition). They are under-used. Two clear situations:

1. As add-on (combination therapy): when an XOI at maximal dose has not reached target, adding a uricosuric to the XOI is more effective than either alone and is preferred to abandoning a partially effective XOI.
2. As an alternative: when both XOIs are not tolerated or contraindicated — especially in confirmed under-excretors with adequate renal function.

The agents: probenecid (widely available; loses efficacy at eGFR <30–50; avoid with urolithiasis); benzbromarone (potent, usable in mild–moderate renal impairment, available in Singapore, but monitor LFTs for idiosyncratic hepatotoxicity); sulfinpyrazone (a further option). Before/during: ensure adequate renal function, maintain good urine volume/hydration, and avoid in urolithiasis or marked hyperuricosuria (stone risk) — a 24-hour urinary uric acid helps if unsure. Losartan and fenofibrate are useful mildly-uricosuric adjuncts when needed for comorbidity. (Lesinurad was withdrawn in 2019; dotinurad is approved in Japan but not yet routine here.)

Combination therapy

When a single agent at maximum dose falls short, XOI + uricosuric is the standard combination and resolves most remaining cases. Persisting above target despite an optimised, adherent combination is what genuinely refractory gout looks like — and the trigger for referral.

6. Acute flare and prophylaxis

Choose the anti-inflammatory by comorbidity, not by habit — the dosing helper does this for a given eGFR and comorbidity profile:

• NSAID (naproxen 500 mg BD or etoricoxib 120 mg OD, 5–7 days, with a PPI) — avoid in eGFR <30, CVD/heart failure, peptic ulcer disease, or anticoagulation.
• Colchicine — low-dose only: 1.0–1.2 mg at onset, 0.5–0.6 mg one hour later, then 0.5–0.6 mg once–twice daily until settled. Reduce in renal impairment (0.5 mg alternate-day if eGFR <30) and avoid with CYP3A4/P-gp inhibitors (macrolides, azoles, ciclosporin, verapamil/diltiazem). The old high-dose regimen is obsolete.
• Corticosteroid (prednisolone 30–35 mg/day for 5 days, or intra-articular for a single large joint) — often safest when NSAIDs and colchicine are limited.

Flare prophylaxis is mandatory when starting or escalating ULT: colchicine 0.5 mg once–twice daily (renally adjusted; low-dose NSAID or prednisolone if unsuitable) for 3–6 months. Mobilisation flares are expected — frame them for the patient as a sign the treatment is working.

7. HLA-B*5801 in the Singapore context

This is where local practice diverges most, and where we add the most value. Carriers face an ~80–100-fold increased risk of allopurinol-induced SCAR (SJS/TEN/DRESS). Local prevalence is high — around 18.5% overall (roughly 1 in 5 Chinese, 1 in 15 Malays, 1 in 25 Indians).

The guidelines disagree: APLAR 2021 suggests testing wherever prevalence is ≥5% (most Singaporeans); ACE Singapore / MOH–HSA keep testing targeted, not universal (PPV only ~2%, limited alternatives, not cost-effective universally — Dong 2015), considering it in higher-risk patients (renal impairment, older age — roughly two-thirds of HSA's SCAR cases were ≥60 and two-thirds had renal impairment); NICE recommends no routine testing; ACR conditionally tests Southeast-Asian and African-American patients.

In practice, run a documented shared decision (the HLA-B*5801 decision aid operationalises this): offer testing especially to higher-risk patients; if positive, declined or unavailable, febuxostat is the test-free alternative; and whatever the route, start low, go slow, and counsel every patient to stop allopurinol and seek care for rash, mucosal ulcers, fever or facial swelling in the first eight weeks. Genotyping is unnecessary in patients already tolerating allopurinol beyond three months.

8. The hard-to-manage gout pathway

This is the centre of the article. Work through it in order.

Step 1 — Audit the basics (before blaming the drug)

Most apparent failure resolves here. Confirm, using the difficult-gout audit: (1) adherence — taking ULT daily, understands it is lifelong; (2) dose — titrated beyond a fixed low dose, often past 300 mg; (3) target — serial urate checked and dosed to <0.36 (<0.30 with tophi); (4) prophylaxis — 3–6 months given; (5) provoking factors — diuretics (losartan substitute?), alcohol, weight; (6) diagnosis secure (exclude CPPD, sepsis, psoriatic); (7) barriers — CKD dosing, intolerance/HLA addressed.

Step 2 — Optimise oral ULT

Maximise allopurinol → switch to or add febuxostat → add a uricosuric (combination XOI + uricosuric), per §5. The majority of "difficult" patients reach target here.

Step 3 — Genuinely refractory or severe tophaceous disease

Reserved for the patient who remains above target with ongoing disease activity despite an optimised, adherent combination oral regimen, or who cannot take oral ULT at all. Pegloticase (recombinant uricase, IV) produces dramatic urate lowering and tophus regression.

It is a specialist therapy for good reasons: G6PD deficiency must be excluded (haemolysis risk); infusion reactions/anaphylaxis need premedication and monitoring; and a pre-infusion serum urate "stopping rule" is used (a rising urate signals anti-drug antibodies). The MIRROR trial showed that co-administering methotrexate (15 mg/week, started before the first infusion) raises durable response from 38.5% to 71% and cuts infusion reactions from 31% to 4% — immunomodulation must precede the first dose. ACR strongly recommends switching to pegloticase in this group, and strongly against first-line use. IL-1 inhibitors (anakinra, canakinumab) are an option for refractory flares when colchicine, NSAIDs and steroids are ineffective or contraindicated.

Gout in chronic kidney disease

CKD constrains NSAIDs and colchicine and complicates dosing, but the principles hold: allopurinol low-start with slow up-titration to the same target, prophylaxis with renally-adjusted colchicine or low-dose steroid, benzbromarone as a renally-tolerant uricosuric option, and a low threshold to involve nephrology/rheumatology (G-CAN 2021).

Tophi

Large or complicated tophi (ulceration, infection, mechanical/nerve compression) warrant surgical referral alongside aggressive urate lowering to dissolve the crystal load.

9. Comorbidity and medication review

Gout sits squarely in the cardiovascular-kidney-metabolic (CKM) cluster. At least annually, review blood pressure, glucose, lipids, renal function and weight. Where feasible, switch urate-raising drugs — thiazide/loop diuretics raise urate; losartan has a mild uricosuric effect and is a useful substitute. Low-dose aspirin modestly raises urate but is rarely stopped for that alone. Encourage 2–3 litres of water daily unless fluid-restricted.

10. Laboratory work-up and monitoring

The dosing & labs tool includes a copy-paste order set. Baseline: serum urate (recheck 2–4 weeks post-flare), renal panel, FBC, LFTs, HbA1c/glucose, lipids; consider HLA-B*5801 before allopurinol in higher-risk patients; selected patients, a 24-hour urinary uric acid. Monitoring: urate every 2–4 weeks while titrating, then 3–6 monthly; renal panel, FBC and LFTs with dose changes; SCAR review in the first 8 weeks; annual CKM review.

11. When to refer

• Diagnostic uncertainty or suspected septic arthritis (urgent).
• Treatment failure — not at target despite optimised, adherent, combination oral ULT.
• Severe or tophaceous disease, erosive damage, or pegloticase candidacy (§8).
• Significant CKD (eGFR <30 / CKD 3b–5) complicating dosing, or transplant patients.
• Allopurinol intolerance/SCAR, or complex HLA-B*5801-positive cases.

12. Using these tools in your practice

The four tools accompanying this guide are free, self-contained web pages that store no patient data — use and adapt them in your own clinic:

• Treat-to-target toolkit — allopurinol titration, urate tracker, difficult-gout audit.
• HLA-B*5801 decision aid — the Singapore shared-decision pathway.
• Dosing & labs — renal-aware flare/prophylaxis dosing and the lab order set.
• Patient handouts — printable flare action plan, uric-acid tracker, and Singapore diet card.

For patients, point them to the plain-language companion at ktmc.sg/education/gout.

13. Guideline comparison (condensed)

All endorse treat-to-target, low-dose colchicine for flares, 3–6 months prophylaxis on ULT initiation, and pegloticase for refractory tophaceous disease.

References

Guidelines

1. FitzGerald JD, et al. 2020 ACR Guideline for the Management of Gout. Arthritis Care Res. 2020;72(6):744–760. doi:10.1002/acr.24180
2. Richette P, et al. 2016 updated EULAR recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42. doi:10.1136/annrheumdis-2016-209707
3. Richette P, et al. 2018 updated EULAR recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31–38. doi:10.1136/annrheumdis-2019-215315
4. Hui M, et al. BSR Guideline for the Management of Gout. Rheumatology. 2017;56(7):e1–e20. doi:10.1093/rheumatology/kex156
5. NICE. Gout: diagnosis and management. NICE guideline NG219. 2022.
6. Agency for Care Effectiveness, MOH Singapore. Gout — achieving the management goal. ACE Clinical Guidance. Updated Dec 2023.
7. Lorenzo JPP, et al. 2021 APLAR clinical practice guideline for treatment of gout. Int J Rheum Dis. 2022;25(1):7–20. doi:10.1111/1756-185X.14266
8. 2024 Update of Chinese Guidelines for Hyperuricemia and Gout, Part I. Int J Rheum Dis. 2025;28(7):e70375. doi:10.1111/1756-185X.70375

HLA-B*5801 / safety

9. MOH–HSA Drug Safety Information No. 59: Role of HLA-B*5801 genotyping prior to allopurinol. 2016 (reminder 2021).
10. Dong D, et al. Cost-effectiveness of HLA-B*5801 genotyping in gout patients starting allopurinol in Singapore. Pharmacogenomics. 2015;16(16):1781–93. doi:10.2217/pgs.15.125
11. Ng WL, et al. HLA-B*58:01 screening in Asia-Pacific is an ethical imperative. J Glob Health. 2025;15:03037. doi:10.7189/jogh.15.03037

Therapy & hard-to-manage gout

12. White WB, et al. Cardiovascular safety of febuxostat or allopurinol in gout (CARES). N Engl J Med. 2018;378:1200–1210. doi:10.1056/NEJMoa1710895
13. Mackenzie IS, et al. Long-term cardiovascular safety of febuxostat vs allopurinol (FAST). Lancet. 2020;396:1745–1757. doi:10.1016/S0140-6736(20)32234-0
14. Botson JK, et al. Methotrexate to increase response to pegloticase (MIRROR): primary findings. Arthritis Rheumatol. 2023;75(2):293–304. doi:10.1002/art.42335
15. Botson JK, et al. MIRROR: 12-month findings. ACR Open Rheumatol. 2023;5(8):407–418. doi:10.1002/acr2.11578
16. Keenan RT, et al. How URAT1 inhibitors can shape the future of chronic gout treatment. Explor Musculoskeletal Dis. 2024;2:529–554. doi:10.37349/emd.2024.00077
17. Stamp LK, et al. Management of gout in CKD: a G-CAN consensus on research priorities. Nat Rev Rheumatol. 2021;17(10):633–641. doi:10.1038/s41584-021-00657-4
18. Bursill D, et al. G-CAN consensus on labels and definitions for disease elements in gout. Arthritis Care Res. 2019;71(3):427–434. doi:10.1002/acr.23607
19. Becker MA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout (FACT). N Engl J Med. 2005;353(23):2450–2461. doi:10.1056/NEJMoa050373
20. Becker MA, et al. Urate-lowering efficacy and safety of febuxostat in gout (CONFIRMS). Arthritis Res Ther. 2010;12(2):R63. doi:10.1186/ar2978
21. Saito Y, et al. Effects of xanthine oxidase inhibition by febuxostat on lipid profiles (PRIZE sub-analysis). Nutrients. 2024;16(14):2324. doi:10.3390/nu16142324
22. Kimura K, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia (FEATHER). Am J Kidney Dis. 2018;72(6):798–810. doi:10.1053/j.ajkd.2018.06.028